BioDelivery Sciences (BDSI) Misses Q3 EPS by 5c

BioDelivery Sciences (NASDAQ: BDSI) reported Q3 EPS of ($0.39), $0.05 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $1.56 million.

Key Anticipated Remaining 2015 and Early 2016 Milestones

• Buprenorphine Depot Injection (maintenance treatment of opioid dependence/chronic pain)
• Pre-IND meeting in November
• Clonidine Topical Gel (treatment of painful diabetic neuropathy)
• Phase 2B study planned to begin by the end of 2015
• Launch of BELBUCA by partner Endo Pharmaceuticals anticipated in the first quarter of 2016

For earnings history and earnings-related data on BioDelivery Sciences (BDSI) click here.

You May Also Be Interested In

• Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
• RBC Capital Reiterates Outperform Rating on Verisk Analytics (VRSK)
• Tompkins Financial (TMP) Tops Q3 EPS by 5c